Filtered By:
Specialty: Pharmaceuticals
Cancer: Cancer
This page shows you your search results in order of date.
Order by Relevance | Date
Total 41 results found since Jan 2013.
Antidepressant use in people with both physical health problems and depression
Many people with diseases such as cancer or diabetes or those who have had a heart attack or stroke also suffer from depression. How effective are antidepressants for these patients? And are they just as safe for these people as for those without physical health problems? Researchers from Charité - Universitätsmedizin Berlin and Aarhus University in Denmark have teamed up to investigate these questions.
Source: World Pharma News - September 8, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Uncontrolled Heart Risk Factors Common in Head, Neck Squamous Cell Cancer
THURSDAY, June 29, 2023 -- The burden of suboptimally controlled cardiovascular (CV) risk factors and incident risk of stroke and myocardial infarction (MI) are considerable in patients with head and neck squamous cell carcinoma (HNSCC), according...
Source: Drugs.com - Pharma News - June 29, 2023 Category: Pharmaceuticals Source Type: news
Cancer Patients Who Continue Smoking After Diagnosis at Risk of CVD Events
FRIDAY, June 2, 2023 -- Cancer patients who continue smoking after their diagnosis have an increased risk for heart attack, stroke, or death due to cardiovascular disease (CVD) compared with nonsmokers, according to a study published online June 1...
Source: Drugs.com - Pharma News - June 2, 2023 Category: Pharmaceuticals Source Type: news
CVD Events Increased for Cancer Patients Who Continue Smoking After Diagnosis
FRIDAY, June 2, 2023 -- Cancer patients who continue smoking after their diagnosis have an increased risk for heart attack, stroke, or death due to cardiovascular disease (CVD) compared with nonsmokers, according to a study published online June 1...
Source: Drugs.com - Pharma News - June 2, 2023 Category: Pharmaceuticals Source Type: news
Why You Should Pay Attention To Diabetes
This means that more than 1 in 3 Americans has prediabetes, which is more than the number of Americans that have cancer, heart disease, or stroke.
Source: Forbes.com Healthcare News - June 1, 2023 Category: Pharmaceuticals Authors: Omer Awan, Contributor Tags: Healthcare /healthcare Innovation /innovation standard Source Type: news
ERLEADA ® (apalutamide), First-and-Only Next-Generation Androgen Receptor Inhibitor with Once-Daily, Single-Tablet Option, Now Available in the U.S.
HORSHAM, Pa., April 3, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the availability of an additional tablet strength of ERLEADA® (apalutamide) in the United States. The introduction of the 240mg tablet provides the first-and-only option for a once-daily, single-tablet Androgen Receptor Inhibitor (ARI) approved for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).With two strengths available, healthcare professionals will have the flexibility to...
Source: Johnson and Johnson - April 3, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Has The Obesity Epidemic Gotten Out Of Hand In America?
Obesity is linked to a number of health ailments, including diabetes, heart disease, stroke, and a number of cancers such as breast and colorectal. If that wasn ’t enough, the annual medical cost of obesity was nearly 173 billion dollars in 2019 alone.
Source: Forbes.com Healthcare News - January 25, 2023 Category: Pharmaceuticals Authors: Omer Awan, Contributor Tags: Healthcare /healthcare Innovation /innovation Source Type: news
Johnson & Johnson Reports Q4 and Full-Year 2022 Results
NEW BRUNSWICK, N.J. – January 24, 2023 – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2022. “Our full year 2022 results reflect the continued strength and stability of our three business segments, despite macroeconomic challenges,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. “I am inspired by our employees who make a difference in the health and lives of people around the world every day. As we look ahead to 2023, Johnson & Johnson is well-positioned to drive near-term growth, while also investing strategically to deliver long-term value...
Source: Johnson and Johnson - January 24, 2023 Category: Pharmaceuticals Source Type: news
America ’s Obsession With Alcohol- Will It Ever End?
Alcohol use, even at moderate amounts, is linked to a number of medical and health-related issues; including but not limited to an increase risk of cancers such as liver, esophagus, and breast; an increased risk of heart disease, stroke, and high blood pressure.
Source: Forbes.com Healthcare News - January 18, 2023 Category: Pharmaceuticals Authors: Omer Awan, Contributor Tags: Healthcare /healthcare Innovation /innovation Source Type: news
Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
U.S. FDA Approves TECVAYLI ™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., October 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved TECVAYLI™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.1 TECVAYLI™ is a first-in-class, bispecific T-cell engager antibody that is administered as a subcutaneous treatment.1 This off-the-shelf (or ready to use) therapy uses innovative science to ac...
Source: Johnson and Johnson - October 25, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Survey: Noncommunicable Diseases Still Underestimated, Only 59% View Diabetes As Very Harmful
Gallup also found that of those interviewed only 83% considered cancer, 72% considered heart disease and stroke, and 51% considered lung disease to be "very harmful. ”
Source: Forbes.com Healthcare News - October 17, 2022 Category: Pharmaceuticals Authors: Bruce Y. Lee, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation Business /business Food & Drink /food-drink pharma Source Type: news
New ERLEADA ® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
SAN FRANCISCO, Feb. 14, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence data showing the initiation of ERLEADA® (apalutamide) results in high rates of rapid and deep prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC). In a separate post-hoc analysis of the registrational Phase 3 SPARTAN and TITAN studies, rapid and deep PSA responses with ERLEADA® were associated with improvement in patient-reported outcomes (PROs) related to quality of life, physical wellbeing, pain, and fatigue intensity. The...
Source: Johnson and Johnson - February 14, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Data at ASCO GU Demonstrate Longstanding Leadership in Prostate Cancer and Commitment to Advancing Potential New Therapeutic Options for Genitourinary Cancers
Raritan, NJ, Feb. 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that 17 presentations will be featured at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place in San Francisco and virtually from February 17-19. Building on its long-term leadership in prostate cancer, Janssen is committed to advancing innovative treatments and transforming patient experiences, while focusing on research that may drive better outcomes for people across the genitourinary cancer spectrum. Data to be presented include Phase 3 results for the selective ...
Source: Johnson and Johnson - February 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
